Boston Scientific evaluates neurostimulation in treatment of chronic migraine

July 22, 2013 by Arezu Sarvestani

Boston Scientific treats the 1st patient in a clinical trial of its Precision neurostimulation implant in treatment of the pain associated with chronic migraine.

Boston Scientific logo

Massachusetts medical device giant Boston Scientific (NYSE:BSX) announced the start of a new clinical trial to evaluate the use of neurostimulation in treatment of chronic migraines.

Boston Scientific's OPTIMISE trial is a randomized, placebo-controlled study assessing occipital nerve stimulation as a novel approach to treating migraines by masking the pain.

Patients are given a programmable implant that stimulates the greater occipital nerve, a method that has shown promise in early studies for reducing pain associated with chronic migraine.

Sign up to get our free newsletters delivered right to your inbox.

"By directly targeting the occipital nerve with neurostimulation, we are potentially able to offer patients an effective and relatively low-risk therapy," principal investigator Dr. Richard Lipton said in prepared remarks.

The Precision implant has the FDA's investigation device exemption to under clinical testing, and the results of the OPTIMISE trial will be used to support "various regulatory approvals" for the pain management system. The 1st OPTIMISE patient was treated at Mercy Hospital in Springfield, Mo.